Nothing Special   »   [go: up one dir, main page]

RS55504A - Pharmaceutical compositions based on azetidine derivatives - Google Patents

Pharmaceutical compositions based on azetidine derivatives

Info

Publication number
RS55504A
RS55504A YUP-555/04A YUP55504A RS55504A RS 55504 A RS55504 A RS 55504A YU P55504 A YUP55504 A YU P55504A RS 55504 A RS55504 A RS 55504A
Authority
RS
Serbia
Prior art keywords
azetidine
general formula
optionally
azetidine derivative
pharmaceutical compositions
Prior art date
Application number
YUP-555/04A
Other languages
English (en)
Inventor
Sophie Cote
Valerie Bobineau
Maria-Teresa Peracchia
Original Assignee
Aventis Pharma S.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A., filed Critical Aventis Pharma S.A.,
Priority to MEP-166/08A priority Critical patent/MEP16608A/xx
Publication of RS55504A publication Critical patent/RS55504A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Stabilan farmaceutski oblik koji sadrži najmanje jedan derivat azetidina opšte formule (Ia) ili (Ib) gde: Ar je aromatična ili heteroaromatična grupa po potrebi supstituisana sa jednim ili više (C1-C4)alkil, halogen, NO2, CN, (C1-C4)alkoksi ili OH po potrebi u kombinaciji sa drugim aktivnim principom koji je u stanju da potencira dejstvo derivata azetidina opšte formule (Ia) ili (Ib), u sistemu koji se sastoji od još najviše dva glavna ekscipijenta odabraa od površinski aktivnog nejonskog agensa hidrofilnog karaktera koji je u stanju da poveća rastvorljivost derivata azetidina opšte formule (Ia) ili (Ib) i u pojedinim slučajevima aktivan princip koji može da potencira dejstvo derivata azetidina i koji je u stanju da izazove stvaranje koloidnog sistema, uz eventualni dodatak još jednog ekscipijenta lipofilne prirode, što stabilizuje formulaciju. Farmaceutski oblici koji sadrže derivate azetidina formule (Ia) ili (Ib) su posebno korisni zbog visokog afiniteta rečnih derivata prema kanabinoidnim receptorima.
YUP-555/04A 2001-12-21 2002-12-20 Pharmaceutical compositions based on azetidine derivatives RS55504A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-166/08A MEP16608A (en) 2001-12-21 2002-12-20 Pharmaceutical compositions based on azetidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0116638A FR2833842B1 (fr) 2001-12-21 2001-12-21 Compositions pharmaceutiques a base de derives d'azetidine
PCT/FR2002/004514 WO2003053431A2 (fr) 2001-12-21 2002-12-20 Compositions pharmaceutiques a base de derives d'azetidine

Publications (1)

Publication Number Publication Date
RS55504A true RS55504A (en) 2007-06-04

Family

ID=8870824

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-555/04A RS55504A (en) 2001-12-21 2002-12-20 Pharmaceutical compositions based on azetidine derivatives

Country Status (32)

Country Link
EP (1) EP1458413B1 (sr)
JP (1) JP5021887B2 (sr)
KR (1) KR20040068308A (sr)
CN (1) CN100388918C (sr)
AP (1) AP1754A (sr)
AR (1) AR037687A1 (sr)
AU (1) AU2002364866B2 (sr)
BR (1) BR0215048A (sr)
CA (1) CA2470443A1 (sr)
CO (1) CO5590911A2 (sr)
DE (1) DE60233071D1 (sr)
DK (1) DK1458413T3 (sr)
EA (1) EA006510B1 (sr)
EC (1) ECSP045162A (sr)
FR (1) FR2833842B1 (sr)
HK (1) HK1070840A1 (sr)
HR (1) HRP20040575A2 (sr)
HU (1) HUP0402586A3 (sr)
IL (1) IL162563A0 (sr)
MA (1) MA27086A1 (sr)
ME (1) MEP16608A (sr)
MX (1) MXPA04005558A (sr)
MY (1) MY138172A (sr)
NO (1) NO20042781L (sr)
NZ (1) NZ533225A (sr)
OA (1) OA12750A (sr)
PL (1) PL203248B1 (sr)
RS (1) RS55504A (sr)
TW (1) TWI256304B (sr)
UA (1) UA77736C2 (sr)
WO (1) WO2003053431A2 (sr)
ZA (1) ZA200404338B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
KR20060124756A (ko) 2004-02-17 2006-12-05 라보라토리오스 델 드라. 에스테브.에스.에이. 치환된 아제티딘 화합물, 그 제조 및 약제로써의 용도
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
FR2923719B1 (fr) * 2007-11-15 2009-11-20 Sanofi Aventis Compositions pharmaceutiques a base de derives d'azetidine
FR2928149B1 (fr) 2008-02-29 2011-01-14 Sanofi Aventis Composes derives d'azetidines, leur preparation et leur application en therapeutique
FR2946650B1 (fr) * 2009-06-16 2011-08-19 Sanofi Aventis Esters derives d'azetidines, leur preparation et leur application en therapeutique.
UA153183U (uk) 2022-10-27 2023-05-31 Андрій Валерійович Максимов Стаканчик для приготування напою

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR73668B (sr) * 1978-11-21 1984-03-28 Hoffmann La Roche
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HRP980026A2 (en) * 1998-01-20 1999-10-31 Pliva Pharm & Chem Works 1-izothiazolydinone derivatives of azetidine-2-ones, processes for the preparation and use thereof
CA2302735A1 (en) * 1998-07-14 2000-01-27 Em Industries, Inc. Microdisperse drug delivery systems
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Also Published As

Publication number Publication date
JP5021887B2 (ja) 2012-09-12
FR2833842B1 (fr) 2004-02-13
MXPA04005558A (es) 2004-12-06
NO20042781L (no) 2004-09-20
MA27086A1 (fr) 2004-12-20
PL372708A1 (en) 2005-07-25
CA2470443A1 (fr) 2003-07-03
HUP0402586A2 (hu) 2005-03-29
OA12750A (fr) 2006-07-03
EA200400843A1 (ru) 2004-12-30
AR037687A1 (es) 2004-12-01
UA77736C2 (en) 2007-01-15
ECSP045162A (es) 2004-08-27
KR20040068308A (ko) 2004-07-30
AP1754A (en) 2007-07-18
HUP0402586A3 (en) 2011-05-30
AU2002364866B2 (en) 2006-11-30
ZA200404338B (en) 2005-06-02
EA006510B1 (ru) 2005-12-29
WO2003053431A2 (fr) 2003-07-03
EP1458413B1 (fr) 2009-07-22
BR0215048A (pt) 2004-11-03
IL162563A0 (en) 2005-11-20
CN100388918C (zh) 2008-05-21
JP2005516945A (ja) 2005-06-09
NZ533225A (en) 2007-02-23
CN1602206A (zh) 2005-03-30
MEP16608A (en) 2010-06-10
TWI256304B (en) 2006-06-11
DK1458413T3 (da) 2009-11-23
TW200301108A (en) 2003-07-01
MY138172A (en) 2009-04-30
EP1458413A2 (fr) 2004-09-22
HK1070840A1 (en) 2005-06-30
PL203248B1 (pl) 2009-09-30
AU2002364866A1 (en) 2003-07-09
CO5590911A2 (es) 2005-12-30
FR2833842A1 (fr) 2003-06-27
DE60233071D1 (de) 2009-09-03
AP2004003066A0 (en) 2004-06-30
WO2003053431A3 (fr) 2003-12-18
HRP20040575A2 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
AP1754A (en) Pharmaceutical compositions based on azetidine derivatives.
MY136855A (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
AU7315301A (en) Compounds and compositions for delivering active agents
PL367618A1 (en) 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht 7 serotonin receptors
CO5560559A2 (es) Formulacion de suspension oral estabilizada
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NO20000466L (no) Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
EP1349545A4 (en) PHARMACEUTICAL COMPOSITIONS OF FENRETINIDE WITH INCREASED BIOAVAILABILITY AND METHOD FOR THEIR USE
WO2002015959A3 (en) Compounds and compositions for delivering active agents
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
DK1653923T3 (da) Oral afleveringssystem omfattende en bivæsket skum
DE602007012435D1 (de) Leukämie
HUP0301334A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és taxánokat és/vagy antimetabolitokat tartalmazó kombinált tumorellenes kompozíciók
NO20025901D0 (no) Antipyretisk preparat inneholdende xylitol
TH65152A (th) องค์ประกอบทางเภสัชกรรมที่อยู่บนพื้นฐานของอนุพันธ์อะซีทิดีน
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
DK1010694T3 (da) Spiroimidazolinderivater og deres anvendelse som alfa2-adrenerge antagonister og monoamin-genoptagningsblokkere